Exelgen, a Subsidiary of Commonwealth Biotechnologies, Inc., Announces Two New Major Drug Discovery Collaborations

RICHMOND, Va. & BUDE, England--(BUSINESS WIRE)--Exelgen, Ltd, a wholly owned subsidiary of Commonwealth Biotechnologies, Inc. (CBI) (NASDAQ Capital Market:CBTE) and a leading provider of drug discovery chemistry services and small molecule products, announced today that it has entered into two new drug discovery collaborations: one with a leading US pharmaceutical company and one with a major European pharmaceutical company. Given the proprietary nature of the collaborations both partners declined to be named.